t-226296 has been researched along with Obesity* in 5 studies
1 review(s) available for t-226296 and Obesity
Article | Year |
---|---|
Identification of melanin-concentrating hormone receptor and its impact on drug discovery.
The neuropeptide melanin-concentrating hormone (MCH) was originally isolated from the pituitary of salmon, in which it causes skin paling. MCH is also found abundantly in mammalian neurons, and has been detected in the lateral hypothalamus and zona incerta, brain regions that are at the center of feeding behavior. Acute central administration of MCH leads to a rapid and significant increase in food intake, while MCH expression changes in states of altered energy balance, such as fasting and obesity. Furthermore, MCH knockout mice tend toward hypophagia and leanness. In 1999, we and four other groups identified an orphan G-protein-coupled receptor (GPCR) as a specific receptor for MCH (MCH-1 receptor). Although a second MCH receptor (MCH-2 receptor) was isolated in humans, it was found to be non-functional or encode a non-functional pseudogene in non-human species, including rodents. The discovery of these MCH receptors permitted the launch of a broad array of drug screening efforts and three MCH-1 receptor antagonists were identified to reduce food intake and body weight. Interestingly, some antagonists unexpectedly produced evidence that blockade of these receptors has antidepressant and anxiolytic activities. The expressions of the MCH receptors, which have been implicated in regulating emotion, stress and motivation, make MCH an excellent candidate for integrating the various homeostatic stimuli necessary for maintaining the proper conditions of energy metabolism and other physiological functions. Finally, the speed at which MCH receptor studies have been undertaken exemplifies the impact that this deorphanized GPCR will have on setting the stage for more detailed physiological studies. Topics: Animals; Anti-Obesity Agents; Biphenyl Compounds; Body Weight; Humans; Hypothalamic Hormones; Melanins; Naphthalenes; Obesity; Piperidines; Pituitary Hormones; Pyrimidines; Receptors, Pituitary Hormone | 2006 |
4 other study(ies) available for t-226296 and Obesity
Article | Year |
---|---|
Melanin concentrating hormone receptor 1 (MCHR1) antagonists-Still a viable approach for obesity treatment?
Obesity is a global epidemic associated with multiple severe diseases. Several pharmacotherapies have been investigated including the melanin concentrating hormone (MCH) and its receptor 1. The development of MCHR1 antagonists are described with a specific perspective on different chemotypes investigated in efforts to overcome hERG liabilities while having orally active, potent and selective compounds with sufficient brain penetration. A chemometric comparison of ∼2000 diverse MCHR1 and ∼1000 diverse hERG ligands underline the structural similarities. A binding pocket analysis of a MCHR1 model and recent X-ray structures of GPCRs invoked in selectivity issues indicate a way to support future drug design. Topics: Anti-Obesity Agents; Biphenyl Compounds; Crystallography, X-Ray; Drug Design; Ether-A-Go-Go Potassium Channels; Humans; Models, Molecular; Molecular Structure; Naphthalenes; Obesity; Piperidines; Pyrimidines; Receptors, Somatostatin; Structure-Activity Relationship | 2012 |
Melanin-concentrating hormone receptor 1 antagonists: synthesis, structure-activity relationship, docking studies, and biological evaluation of 2,3,4,5-tetrahydro-1H-3-benzazepine derivatives.
Melanin-concentrating hormone receptor 1 (MCHR1) antagonists have been studied as potential agents for the treatment of obesity. Initial structure-activity relationship studies of in-house hit compound 1a and subsequent optimization studies resulted in the identification of tetrahydroisoquinoline derivative 23, 1-(2-acetyl-1,2,3,4-tetrahydroisoquinolin-7-yl)-4-[4-(4-chlorophenyl)piperidin-1-yl]butan-1-one, as a potent hMCHR1 antagonist. A homology model of hMCHR1 suggests that these compounds interact with Asn 294 and Asp 123 in the binding site of hMCHR1 to enhance binding affinity. Oral administration of compound 23 dose-dependently reduced food intake in diet-induced obesity (DIO)-F344 rats. Topics: Animals; Anti-Obesity Agents; Benzazepines; CHO Cells; Cricetinae; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Dynamics Simulation; Obesity; Protein Binding; Rats; Rats, Inbred F344; Receptors, Pituitary Hormone; Spectrometry, Mass, Electrospray Ionization; Structure-Activity Relationship | 2011 |
Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics.
Melanin concentrating hormone (MCH) is involved in regulation of food intake and energy homeostasis. Antagonists of the MCH receptor are expected to affect food intake and weight gain, making MCH-R1 an attractive target for obesity treatment. Herein, we report the discovery of a novel, orally active series of MCH-R1 antagonists that exhibit in vivo efficacy in rodent obesity models. Topics: Administration, Oral; Animals; Anti-Obesity Agents; Biological Availability; Brain; Bridged Bicyclo Compounds; Cycloheptanes; Cyclohexanes; Eating; Mice; Obesity; Rats; Receptors, Pituitary Hormone; Receptors, Somatostatin; Urea | 2005 |
Melanin-concentrating hormone-1 receptor antagonism decreases feeding by reducing meal size.
Prior work has demonstrated that melanin-concentrating hormone-1 (MCH-1) receptor antagonism decreases food intake and body weight in obese rodents. The purpose of this study was to determine if the MCH-1 receptor antagonist-mediated hypophagia was due a decrease in meal size, meal frequency, or both. We performed a meal pattern analysis in free-feeding hyperphagic diet-induced obese (DIO) rats treated with 1, 3 or 10 mg/kg p.o. of the MCH-1 receptor antagonist T-226296 (a (-)enantiomer of N-[6-(dimethylamino)-methyl]-5,6,7,8-tetrahydro-2-naphthalenyl]-4'-fluoro[1,1'-biphenyl]-4 carboxamide). Food intake was continuously monitored for 24 h using a BioDAQ food intake monitoring system. A total of 10 mg/kg T-226296 significantly decreased body weight and 24-h food intake, and had no effect on locomotor activity. The decrease in food intake was due to a reduction in meal size, not meal frequency. We conclude that MCH-1 receptor antagonism with T-226296 decreases food intake in DIO rats by selectively reducing meal size, and that the reduced food intake is not due to a generalized behavioral malaise. Topics: Animals; Biphenyl Compounds; Body Weight; Dose-Response Relationship, Drug; Eating; Feeding Behavior; Male; Motor Activity; Naphthalenes; Obesity; Rats; Rats, Sprague-Dawley; Receptors, Pituitary Hormone; Stereoisomerism; Time Factors | 2004 |